Table 4.
Antibiotic susceptibility of Pseudomonas aeruginosa bloodstream infection isolates, and the definitive antibiotic therapy used during the study period
| Antibiotic | Susceptibility of PA isolates to anti-pseudomonal antibiotics | Antibiotics used as definitive antibiotic therapy | ||||
|---|---|---|---|---|---|---|
| HAI N = 60 n/N (%) |
IPOA N = 31 n/N (%) |
Total N = 91 n/N (%) |
HAI N = 60 n/N (%) |
IPOA N = 31 n/N (%) |
Total N = 91 n/N (%) |
|
| Gentamicin | 43 (71.7) | 28 (90.3) | 71 (78.0) | 5 (8.3) | 2 (6.5) | 7 (7.7) |
| Amikacin | 50 (83.3) | 28 (90.3) | 78 (85.7) | 10 (16.7) | 6 (19.4) | 16 (17.6) |
| Ciprofloxacin | 42 (70.0) | 28 (90.3) | 70 (76.9) | 12 (20.0) | 7 (22.6) | 19 (20.9) |
| Piperacillin-tazobactam | 35 (58.3) | 19 (61.3) | 54 (59.3) | 12 (20.0) | 9 (29.0) | 21 (23.1) |
| Ceftazidime | 50 (83.3) | 29 (93.5) | 79 (86.8) | 8 (13.3) | 8 (25.8) | 16 (17.6) |
| Cefepime | 47 (78.3 | 26 (83.9) | 73 (80.2) | 11 (18.3) | 2 (6.5) | 13 (14.3) |
| Meropenem | 44 (73.3) | 28 (90.3) | 72 (79.1) | 27 (45.0) | 10 (32.3) | 37 (40.7) |
|
Imipenem Colistin |
43 (71.7) - |
27 (87.1) - |
70 (76.9) - |
2 (3.3) 9 (15) |
0 (0) - |
2 (2.2) 9 (9.9) |
PA Pseudomonas aeruginosa, HAI Healthcare-associated infection, IPOA Infection present on admission.